Xeris Pharmaceuticals Stock Analysis

Xeris Stock Analysis Notes

About 43.0% of the company outstanding shares are owned by institutional investors. The company recorded a loss per share of 0.37. Xeris Pharmaceuticals had not issued any dividends in recent years. The entity had 1:1 split on the 6th of October 2021. Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. Xeris Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 294 people. For more information please call Paul Edick at 844 445 5704 or visit https://www.xerispharma.com.

Xeris Pharmaceuticals Investment Alerts

Xeris Pharmaceuticals Upcoming and Recent Events

Xeris Largest EPS Surprises

View All Earnings Estimates

Xeris Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Xeris Stock Institutional Investors

Note, although Xeris Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Xeris Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 741.99 M.

Xeris Profitablity

The company has Profit Margin (PM) of (0.27) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.13 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.13.

Management Efficiency

Xeris Pharmaceuticals has return on total asset (ROA) of (0.0533) % which means that it has lost $0.0533 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.1716) %, meaning that it created substantial loss on money invested by shareholders. Xeris Pharmaceuticals' management efficiency ratios could be used to measure how well Xeris Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 1.94 in 2025, whereas Return On Tangible Assets are likely to drop (0.29) in 2025. At this time, Xeris Pharmaceuticals' Non Currrent Assets Other are comparatively stable compared to the past year. Other Assets is likely to gain to about 5.7 M in 2025, despite the fact that Net Tangible Assets are likely to grow to (84 M).

Technical Drivers

As of the 17th of March 2025, Xeris Pharmaceuticals maintains the Downside Deviation of 2.77, mean deviation of 2.27, and Market Risk Adjusted Performance of 0.884. Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Xeris Pharmaceuticals, as well as the relationship between them. Please check out Xeris Pharmaceuticals jensen alpha and semi variance to decide if Xeris Pharmaceuticals is priced fairly, providing market reflects its latest price of 4.82 per share. Given that Xeris Pharmaceuticals has jensen alpha of 0.5052, we strongly advise you to confirm Xeris Pharmaceuticals's prevalent market performance to make sure the company can sustain itself at a future point.

Xeris Pharmaceuticals Price Movement Analysis

Xeris Pharmaceuticals Insider Trading Activities

Xeris Pharmaceuticals Outstanding Bonds

Xeris Pharmaceuticals Predictive Daily Indicators

Xeris Pharmaceuticals Corporate Filings

Xeris Pharmaceuticals Forecast Models

Xeris Pharmaceuticals' time-series forecasting models are one of many Xeris Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Xeris Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Xeris Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Xeris shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Xeris Pharmaceuticals. By using and applying Xeris Stock analysis, traders can create a robust methodology for identifying Xeris entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Xeris analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Xeris analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Xeris Pharmaceuticals stock analysis indicators help investors evaluate how Xeris Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Xeris Pharmaceuticals shares will generate the highest return on investment. By understating and applying Xeris Pharmaceuticals stock analysis, traders can identify Xeris Pharmaceuticals position entry and exit signals to maximize returns.

When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.